Studies of how long people stay on GLP-1 treatment can count uninterrupted refills, a prescription covering a particular date or completion of a trial. Those definitions help explain why the reported numbers for adolescents differ.
What the U.S. claims study measured
Researchers followed a cohort of 1,139 pediatric patients and 201,229 adults with obesity and no diabetes using U.S. commercial insurance claims from 2021 to 2023. They grouped people by monthly prescription coverage over the year after starting treatment. Among pediatric patients, 20.3% fell into the persistent-user group, compared with 30.7% of adults [1]. Others had different refill patterns, including intermittent coverage. The study could not determine which doses people took or why they had gaps.
What the Danish prescription registry found
At one year, 54% of the adolescents ages 12 to 17 and 37% of the young adults ages 18 to 24 had estimated prescription coverage. That allowed for a gap followed by a restart. Across both age groups, 38% had estimated coverage and 22% had stayed on treatment without a gap under the study definition [2]. The Danish study included multiple drugs and some patients with diabetes, so its rates cannot be directly compared with the U.S. data.
What happened in STEP TEENS?
The review of lifestyle treatment and obesity medicines in teens compares weight outcomes across several treatment approaches. The claims studies above measured how long people kept filling prescriptions.
In STEP TEENS, 180 of 201 randomized participants completed 68 weeks of assigned treatment, about 90% in both the semaglutide and placebo groups [3]. Both groups received lifestyle support and followed the study schedule. Completion in this setting does not establish how many adolescents would keep filling prescriptions in routine care.
If prescription access, side effects or treatment goals change, families can discuss next steps with the clinician managing the adolescent’s care.